CogImpCKD
Research type
Research Study
Full title
Burden And Impact Of Undiagnosed Cognitive Impairment In A Multi-ethnic Population With Advanced Chronic Kidney Disease
IRAS ID
331628
Contact name
Pushpen Joshi
Contact email
Sponsor organisation
University College London
Clinicaltrials.gov Identifier
Z6364106/2024/07/87 health research, UCL data protection regsitration
Duration of Study in the UK
2 years, 11 months, 28 days
Research summary
Cognitive impairment (CI) refers to a decline in one or more areas of memory. People with chronic kidney disease (CKD) are at higher risk of CI than the general population, however, studies suggests it is often under-diagnosed. This may have important implications for how people manage their condition and make complex, treatment-related decisions; a particular concern amongst those approaching dialysis.This study aims to quantify the prevalence of undiagnosed CI within a diverse population with advanced CKD. Secondly, it aims to identify those groups most at risk of under-diagnosis. Finally, we aim to investigate how undiagnosed CI effects treatment decision-making and clinical and quality of life outcomes, following start of dialysis or a decision to have supportive care.
A qualitative component, made up of semi-structured interviews, will run in parallel to the chort study. The interviews will explore attitudes towards research participation and the cultural, social and economic factors which have influenced patients’ treatment choice and the decision-making process.
Recruitment for the next part of the study will follow. Participants will be recruited from advanced kidney care clinics and will complete a cognitive screening (i.e memory) test, specifically designed for use in multicultural populations, and a questionnaire, covering quality of life and detailed social information. Participants will be followed up by review of the clinical record and data such as treatment choice (i.e dialysis vs supportive care), listing for transplantation, emergency dialysis start and death will be recorded.
Understanding the prevalence of CI, which groups are most at risk and how it effects health and quality of life, will help to identify potential areas for intervention and inform the rationale for future studies. It may also guide clinical practice and health policies, encouraging more individualised and holistic support to patients at a vulnerable point in their journey.
REC name
London - Bromley Research Ethics Committee
REC reference
24/LO/0607
Date of REC Opinion
19 Sep 2024
REC opinion
Further Information Favourable Opinion